Market Place
Sourcing Support
Revolution Meds to Host RASolute 302 Call After Positive Results
21 May 2026 //
GLOBENEWSWIRE
Revolution Medicines Reports Q1 2026 Results and Corporate Update
06 May 2026 //
GLOBENEWSWIRE
Revolution Medicines Presents Daraxonrasib in First-Line at 2026
21 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines To Unveil Daraxonrasib Phase 3 Results
21 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines` Cancer Pill Boosts Late-Stage Survival
13 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines Starts Ph3 RASolute 303 in Pancreatic Cancer
02 Apr 2026 //
GLOBENEWSWIRE
Quanta Shows: Multi-KRAS Inhibitors Beat Pan-RAS Resistance
05 Mar 2026 //
GLOBENEWSWIRE
Revolution Medicines Announces 2025 Results and Updates
25 Feb 2026 //
GLOBENEWSWIRE
Revolution Medicines Starts Rasolute 304 Trial For Daraxonrasib
18 Dec 2025 //
GLOBENEWSWIRE
Revolution Medicines` Daraxonrasib Gets FDA Orphan Status
27 Oct 2025 //
GLOBENEWSWIRE
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236)
16 Oct 2025 //
GLOBENEWSWIRE
Revolution Begin RASolute 303 Trial for Pancreatic Adenocarcinoma
10 Sep 2025 //
GLOBENEWSWIRE
Revolution Wins FDA Breakthrough Tag for Daraxonrasib
23 Jun 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.